Vaccines for tick-borne diseases and cost-effectiveness of vaccination: A public health challenge to reduce the diseases burden

Expert Review of Vaccines

Volumn 15, Issue 1, 2016, Pages 5-7

  Šmit, Renata ^a,b   Postma, Maarten J ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TICK BORNE ENCEPHALITIS VACCINE; BACTERIAL VACCINE; VIRUS VACCINE;

COST EFFECTIVENESS ANALYSIS; HUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; TICK BORNE DISEASE; TREATMENT DURATION; VACCINATION; COST BENEFIT ANALYSIS; ECONOMICS; ENCEPHALITIS, TICK-BORNE; EUROPE; IMMUNOLOGY; LYME DISEASE; PROCEDURES;

BACTERIAL VACCINES; COST-BENEFIT ANALYSIS; ENCEPHALITIS, TICK-BORNE; EUROPE; HUMANS; LYME DISEASE; VACCINATION; VIRAL VACCINES;

EID: 84951569211     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1111142     Document Type: Review

References (20)

1. Institute of Medicine (IOM). 2011. Critical needs and gaps in understanding prevention, amelioration, and resolution of Lyme and other tick-borne diseases: the short-term and long-term outcomes. Washington (DC): The National Academies Press. [ cited 2015 Aug ]. Available from: www.iom.edu.
2. Sprong H, Trentelman J, Seemann I., et al. ANTIDotE: anti-tick vaccines to prevent tick-borne diseases in Europe. Parasit Vectors. 2014; 21: 7-77.
3. Wressnigg N, Pöllabauer E, Aichinger G., et al. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis. 2013; 13: 680-689.
4. Kollaritsch H, Krasilnikov V, Holzmann H., et al. Background document on vaccines and vaccination against tick-borne encephalitis. Geneva: WHO Strategic Advisory Group of Experts on Immunization. [ cited 2011 Sep ]. Available from: www.who.int/immunization/sage/previousapril2011/en/index.html/.
5. Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis. 2001; 52 (Suppl 3): s253-8.
6. Schuijt TJ, Hovius JW, van der Poll T., et al. Lyme borreliosis vaccination: the facts, the challenge, the future. Trends Parasitol. 2011; 27 (1): 40-47.
7. Šmit R. Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults. Vaccine. 2012; 30: 6301-6306.
8. Ola-Engman K, Kallings-Larsson C, Feldman I. Halsoekonomisk analys av allman TBE-vaccinering av inv anarna I Sormland; 2013. [ cited 2013 Aug ]. Available from: http://www.landstingetsormland.se/PageFiles/37448/(9)%20H%C3%A4lsoekonomisk%20analys%20av%20allm%C3%A4n%20TBE-vaccinering%20av%20inv%C3%A5narna%20i%20S%C3%B6rmland.pdf.
9. Askling HH, Insulander M, Hergens MP., et al. Tick borne encephalitis (TBE)-vaccination coverage and analysis of variables associated with vaccination, Sweden. Vaccine. 2015; 33 (38): 4962-4968.
10. Työpaperi. Pitäisikö TBE-rokotusohjelmaa laajentaa? Puutiaisaivokuumerokotustyöryhmän raportti. [ cited 2015 Aug ]. Available from: http://www.julkari.fi/bitstream/handle/10024/110860/URN-ISBN-978-952-245-627-4.pdf?sequence=1.
11. Jürisson M, Taba P, Võrno T., et al. Puukentsefaliidi vastase vaktsineerimise kulutõhusus Eestis. Tartu: Tartu Ülikooli tervishoiu instituut; 2015. The cost-effectiveness of tick-borne encephalitis vaccination in Estonia. [ cited 2015 Aug ]. Available from: http://rahvatervis.ut.ee/bitstream/1/6065/2/TTH13-Tick-borne-encephalitis-vaccination-summary.pdf.
12. Šmit R, Postma MJ. Disability-adjusted life years (DALYs) as a composite measure to express the burden of tick-borne encephalitis (TBE) in Slovenia. Value Health. 2014; 17 (7): A666.
13. Šmit R, Postma MJ. Review of tick-borne encephalitis and vaccines: clinical and economical aspects. Expert Rev Vaccines. 2015; 14: 737-747.
14. Kunze U. TBE-awareness and protection: the impact of epidemiology, changing lifestyle, and environmental factors. Wien Med Wochenschr. 2010; 160: 252-255.
15. Kunz C. TBE vaccination and the Austrian experience. Vaccine. 2003; 21: S50-5.
16. Stanek G, Fingerle V, Hunfeld K., et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol and Infec. 2011; 17 (1): 69-79.
17. Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis. 1999; 5: 321-328.
18. Shadick NA, Liang MH, Phillips CB., et al. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med. 2001; 161: 554-561.
19. Hsia EC, Chung JB, Schwartz JS., et al. Cost-effectiveness analysis of the Lyme disease vaccine. Arthritis Rheum. 2002; 46: 1651-1660.
20. Šmit R, Postma MJ. Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics. Expert Rev Vaccines. 2015; 28: 1-13.